Continuous Glucose Monitoring Market Growth Plan Beyond Insulin Users

Published :   16 Nov 2026  |  Author :  Aditi Shivarkar, Aman Singh  | 
 |  Copy Copy   Print Print

Explore how continuous glucose monitors can improve type 2 diabetes management beyond insulin users through better glucose tracking, personalized lifestyle decisions, and improved treatment monitoring. Discover recent clinical findings, technology developments, adoption challenges, and future opportunities in diabetes care.

Diabetes management is entering a new phase as continuous glucose monitoring (CGM) technology becomes increasingly accessible to people living with type 2 diabetes. Traditionally, these devices were primarily associated with individuals who required insulin for type 2 diabetes. However, growing clinical evidence suggests that continuous glucose monitors may also help people with type 2 diabetes who manage their condition through oral medications, lifestyle modifications, or other non-insulin treatments.

Unlike conventional blood glucose meters that provide readings at specific moments, CGM devices continuously measure glucose levels through small sensors placed under the skin. They provide information about glucose fluctuations throughout the day and night, helping individuals understand how meals, physical activity, sleep, stress, and medications influence blood sugar levels.

According to a study highlighted in The Clinical Times Briefing published on October 18, 2026, continuous glucose monitors improve blood sugar control in people with type 2 diabetes. The finding brings attention to the potential benefits of CGM technology beyond traditional insulin-dependent populations.

This development could influence diabetes care by encouraging more personalized glucose management, improving patient engagement, and helping healthcare professionals make better-informed treatment decisions. As diabetes prevalence continues to increase worldwide, expanding CGM use beyond insulin users could create important opportunities for digital health companies, medical device manufacturers, and healthcare providers.

Understanding Continuous Glucose Monitoring Beyond Insulin Users

Continuous glucose monitoring is a diabetes management technology that measures glucose levels in the fluid surrounding cells through a small wearable sensor. The sensor generally transmits readings to a smartphone, receiver, or compatible device, allowing users and healthcare professionals to observe patterns throughout the day.

Traditional blood glucose monitoring require individuals to prick their fingers and measure glucose levels in the fluid surrounding cells through a small wearable sensor. The sensors generally transmit readings to a smartphone, receiver, or compatible device, allowing users and healthcare professionals to observe glucose patterns throughout the day.

Traditional blood glucose monitoring requires individuals to prick their fingers and measure glucose at particular times, such as before meals or after exercise.

Although this approach remains useful, occasional readings may not capture glucose fluctuations occurring between measurements or during sleep.

CGM technology addresses this limitation by providing continuous information about glucose levels, including:

  • Real-time glucose readings: Users can monitor glucose levels throughout the day without repeatedly performing finger-prick tests.
  • Glucose trend information: The device shows whether glucose levels are increasing, decreasing, or remaining stable.
  • High and low glucose alerts: Certain systems notify users when glucose levels move beyond pre-set thresholds.
  • Time in range: This measurement indicates how much time glucose levels remain within a recommended range, commonly 70-180 mg/dL for many adults with diabetes.
  • Historical glucose reports: Healthcare professionals can review glucose patterns and identify potential relationships between meals, medications, exercise, and blood sugar fluctuations.

For people with type 2 diabetes who do not use insulin, these capabilities could provide additional information that conventional monitoring may miss. Instead of relying exclusively on occasional glucose measurements and periodic HbA1c testing, patients can better understand their daily glucose patterns.

Why Continuous Glucose Monitors Could Improve Type 2 Diabetes Control Beyond Insulin Users

Better Understanding of Daily Glucose Fluctuations

One of the biggest reasons CGM technology is gaining attention beyond insulin users is its ability to reveal glucose fluctuations through the day.

People with type 2 diabetes who manage their condition through oral medications or lifestyle changes may not routinely monitor their glucose levels. However, blood sugar can fluctuate following meals, physical activity, stress, and changes in sleeping patterns.

Continuous monitoring provides a clearer picture of these changes. Patients can identify which meals cause significant glucose increases and understand how their daily routines influence blood sugar control.

This information may encourage more informed lifestyle decisions and help individuals work with healthcare professionals to improve their diabetes management.

Improved HbA1c and Time-in-Range Outcomes

Another important factor is the potential improvements in established measurements of diabetes control. HbA1c reflects average blood glucose levels over approximately three months, while time in range provides information about daily glucose patterns.

A randomized clinical trial published in the New England Journal of Medicine on October 15, 2026, demonstrated meaningful improvement among adults with type 2 diabetes who were not using insulin.

According to MedTech Dive’s October 15, 2026 report, participants using Dexcom G7 CGM experienced an average Hba1c reduction from 8.8% to 7.2% over 26 weeks. In comparison, the routine-care group improved from 8.7% to 8.0%; CGM users also spent approximately five additional hours per day within the target glucose range of 70-180 mg/dL.

These findings suggest that continuous monitoring could become a valuable component of diabetes management even before patients require insulin therapy.

More Personalized Nutrition and Lifestyle Management

Food choices and physical activity play important roles in managing type 2 diabetes. However, glucose responses can differ considerably between individuals, even when they consume similar meals.

CGM devices allow users to observe how their glucose levels respond to different foods, meal timings, and physical activities. This information can help individuals recognize patterns and make practical adjustments under professional guidance.

For example, patients may identify glucose increases following particular carbohydrate-rich meals or observe improvements after walking or exercising.Personalized insights can make lifestyle management more practical because individuals can understand how their everyday decisions influence glucose levels rather than depending entirely on generalized dietary recommendations.

Earlier Intervention Before Insulin Therapy

Continuous glucose monitoring could also support earlier intervention in the progression of type 2 diabetes.

Many patients initially manage their condition through dietary changes, exercise, and non-insulin medications. However, some continue experiencing elevated glucose levels despite treatment.

CGM technology can provide additional information about persistent hyperglycemia and glucose variability, helping healthcare professionals evaluate whether existing treatment strategies are working effectively.

The technology does not replace clinical assessments or determine medication changes independently. Instead, it can provide useful information that supports discussions between patients and healthcare providers.

Earlier identification of poor glucose control may encourage timely treatment adjustments and help prevent prolonged exposure to elevated blood sugar.

Greater Patient Engagement and Self-Management

Another important advantage is improved patient participation in diabetes management.

Traditional monitoring can sometimes feel repetitive because patients receive limited information from individual finger-prick measurements. Continuous glucose monitoring provides visual trends and feedback that can make glucose management easier to understand.

Patients can observe the effects of meals, exercise, medication schedules, and daily habits. These insights may encourage greater involvement in managing their condition.

For healthcare professionals, glucose reports can also support more productive consultations by providing information about a patient's glucose patterns between appointments.

However, effective use requires appropriate education so that patients do not become unnecessarily concerned about normal glucose fluctuations or make treatment changes without medical advice.

Recent Clinical Developments Supporting CGM Adoption

Randomized Trial Demonstrates Benefits Beyond Insulin Users

A major development in October 2026 strengthened the clinical evidence supporting continuous glucose monitoring among non-insulin-treated type 2 diabetes patients.

The randomized trial published in the New England Journal of Medicine evaluated CGM use across 22 primary care practices in the United States. Medical Xpress reported that 283 adults were included in the study, with participants followed for 26 weeks.

The findings showed that people using CGM spent approximately five additional hours each day within their target glucose range compared with those receiving routine care. Nearly twice as many CGM users also achieved an HbA1c level below 7%. 

The study is particularly important because most people with type 2 diabetes receive treatment through primary care settings rather than specialist diabetes centers.

These findings could encourage healthcare providers to consider CGM technology earlier in diabetes management.

Dexcom G7 Strengthens the Case for Wider CGM Adoption

Dexcom G7 is an important example of wearable technology being evaluated for people with type 2 diabetes who do not use insulin.

The device continuously measures glucose levels through a wearable sensor and provides readings through compatible digital devices.

The 2026 clinical trial involving the Dexcom G7 generated additional evidence supporting its potential use in non-insulin-treated populations. The results were consistent across several demographic and treatment-related groups, according to the company's reported findings.

The development could strengthen the position of CGM manufacturers as they explore opportunities beyond traditional insulin-dependent users. 

Potential Expansion of Medicare Coverage

Insurance reimbursement is another important development influencing CGM adoption.

According to MedTech Dive's October 15, 2026 report, Dexcom was awaiting a decision from the Centers for Medicare and Medicaid Services (CMS) regarding expanded Medicare coverage for people with type 2 diabetes who do not use insulin.

The report indicated that expanded coverage could substantially increase the number of eligible users and improve access to glucose monitoring technology. However, the timing and implementation of any coverage expansion remained uncertain. 

Broader reimbursement could reduce financial barriers and encourage more healthcare providers to introduce CGM technology into routine diabetes management.

How Technology is Supporting the Growth of Continuous Glucose Monitoring

Technological advancements are making CGM systems more accessible, connected, and useful for people managing type 2 diabetes. Several innovations are contributing to this transformation.

  • Smartphone integration: Modern CGM devices connect with smartphones and compatible applications, allowing users to view glucose readings, receive alerts, and access historical reports.
  • Cloud-based data sharing: Digital platforms allow patients to share glucose information with healthcare professionals and caregivers, supporting remote monitoring and more informed consultations.
  • Artificial intelligence and predictive analytics: Emerging analytical tools can identify glucose patterns, assess trends, and potentially predict changes in blood sugar levels. These capabilities may support more personalized diabetes management.
  • Wearable sensor advancements: Improvements in sensor design, accuracy, comfort, and usability are helping manufacturers develop devices suitable for longer and more convenient everyday use.
  • Connected healthcare platforms: Integration with electronic health records and digital diabetes management applications can help healthcare providers combine glucose information with medication history, clinical assessments, and lifestyle data.

Together, these technological developments could strengthen the role of CGM systems in preventive healthcare and long-term diabetes management.

Key Challenges That Could Affect CGM Adoption Beyond Insulin Users

Despite promising clinical findings, several challenges could influence the wider adoption of continuous glucose monitoring among people with type 2 diabetes.

High Device Costs and Limited Insurance Coverage

The cost of CGM sensors, transmitters, and replacement supplies can create financial barriers, particularly for individuals who do not use insulin and may not qualify for reimbursement under existing insurance policies.

In countries such as India, affordability could become a significant concern because many patients pay for diabetes monitoring devices directly. Wider availability of affordable sensors and reimbursement programs will be important for expanding access.

Limited Awareness Among Patients and Healthcare Professionals

Many patients continue to associate continuous glucose monitoring primarily with type 1 diabetes and insulin-dependent type 2 diabetes.

Limited awareness about its potential benefits for non-insulin users may slow adoption. Healthcare professionals also require appropriate training to interpret CGM reports and identify patients who could benefit from continuous monitoring.

Accuracy and Data Interpretation

CGM devices measure glucose in interstitial fluid rather than directly measuring blood glucose. Consequently, readings may differ from conventional blood glucose measurements, particularly when glucose levels are changing rapidly.

Patients must understand how to interpret readings, alerts, and trend information. Unexpected symptoms or readings may require confirmation through a blood glucose test, depending on the device instructions and clinical circumstances.

Data Privacy and Cybersecurity

As CGM devices increasingly connect with smartphones, cloud platforms, and digital healthcare systems, protecting patient information becomes essential.Manufacturers must maintain strong cybersecurity measures, secure data-sharing systems, and appropriate privacy protections. Any weakness in digital infrastructure could affect patient confidence and healthcare adoption.

Risk of Information Overload

Continuous access to glucose information can sometimes create anxiety, particularly among individuals who are unfamiliar with interpreting glucose fluctuations.

Not every temporary increase in glucose represents a serious problem. Patients need clear guidance to understand their readings and avoid unnecessary dietary restrictions or medication adjustments.

Healthcare professionals must ensure that CGM technology supports better decision-making rather than creating additional stress.

What the Future Holds for Continuous Glucose Monitoring in Type 2 Diabetes

The future of continuous glucose monitoring will likely involve broader adoption across different diabetes patient populations, including individuals who do not require insulin therapy.

Clinical evidence demonstrating improvements in HbA1c and time in range could encourage healthcare organizations to reconsider when CGM technology should be introduced during type 2 diabetes treatment.

One important opportunity involves integrating CGM into primary care. Since many individuals with type 2 diabetes receive routine treatment through primary care providers, expanding access in these settings could help identify patients who are struggling to achieve recommended glucose targets.The technology may also become increasingly important in personalized diabetes management. Combining glucose information with nutrition tracking, physical activity data, medication records, and digital health applications could help healthcare professionals develop more individualized treatment strategies.

In India, increasing diabetes prevalence creates opportunities for manufacturers to introduce affordable monitoring solutions. Wider availability of locally manufactured sensors, smartphone-connected devices, and digital diabetes management platforms could improve access, particularly among patients who are not currently using insulin.

Another important development could involve insurance coverage expansion. In the United States, potential Medicare reimbursement changes could influence adoption among non-insulin-treated patients. Similar reimbursement discussions and healthcare financing initiatives in other markets could determine how quickly CGM becomes part of routine diabetes care.

Artificial intelligence may further improve the usefulness of CGM systems by identifying recurring glucose patterns and providing personalized insights. However, clinical validation, patient safety, data privacy, and regulatory compliance will remain essential.

Ultimately, the next phase of CGM development will focus not only on measuring glucose continuously but also on making glucose information more meaningful, accessible, and actionable for patients and healthcare professionals.

Conclusion

Continuous glucose monitors could improve type 2 diabetes control beyond insulin users by providing continuous glucose information, identifying daily blood sugar fluctuations, and supporting more personalized lifestyle and treatment decisions.

The October 2026 randomized clinical trial published in the New England Journal of Medicine provides important evidence for this expanding role. Participants using CGM spent approximately five additional hours per day within their target glucose range, while average HbA1c improvements were greater than those observed with routine care. 

Advancements in wearable sensors, smartphone connectivity, artificial intelligence, and cloud-based monitoring may further strengthen the usefulness of these devices. However, affordability, reimbursement limitations, patient awareness, data privacy, and appropriate clinical interpretation remain important challenges.

As diabetes management increasingly moves toward personalized and technology-supported care, continuous glucose monitoring could become a valuable option for people with type 2 diabetes, including those managing their condition without insulin. The central opportunity is to make glucose monitoring more informative and accessible while ensuring that technology translates into meaningful improvements in long-term patient outcomes.

About the Authors

Aditi Shivarkar

Aditi Shivarkar

Aditi, Vice President at Precedence Research, brings over 15 years of expertise at the intersection of technology, innovation, and strategic market intelligence. A visionary leader, she excels in transforming complex data into actionable insights that empower businesses to thrive in dynamic markets. Her leadership combines analytical precision with forward-thinking strategy, driving measurable growth, competitive advantage, and lasting impact across industries.

Aman Singh

Aman Singh

Aman Singh with over 13 years of progressive expertise at the intersection of technology, innovation, and strategic market intelligence, Aman Singh stands as a leading authority in global research and consulting. Renowned for his ability to decode complex technological transformations, he provides forward-looking insights that drive strategic decision-making. At Precedence Research, Aman leads a global team of analysts, fostering a culture of research excellence, analytical precision, and visionary thinking.

Piyush Pawar

Piyush Pawar

Piyush Pawar brings over a decade of experience as Senior Manager, Sales & Business Growth, acting as the essential liaison between clients and our research authors. He translates sophisticated insights into practical strategies, ensuring client objectives are met with precision. Piyush’s expertise in market dynamics, relationship management, and strategic execution enables organizations to leverage intelligence effectively, achieving operational excellence, innovation, and sustained growth.